NCT06639152

Brief Summary

The goal of this clinical trial is to compare the effects of oil-based contrast medium (OBCM) and water-based contrast medium (WBCM) during hysterosalpingography(HSG)on pregnancy outcomes in infertile women. The main question it aims to answer is whether an oil-based contrast medium improves fertility outcomes in infertile women. Participants were divided into those who received an oil-based contrast medium (ethiodized poppyseed oil) and a water-based contrast medium (Ioversol) based on a shared medical decision-making process between patients and healthcare providers. The two contrast agents used in this study are routinely employed in clinical practice and will not affect the participants\' health. Participants are required to complete some clinical questionnaires before and after the HSG procedure to provide clinical information. Other than that, there will be no additional costs for participants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,187

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 4, 2020

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

September 29, 2024

Completed
16 days until next milestone

First Posted

Study publicly available on registry

October 15, 2024

Completed
Last Updated

October 15, 2024

Status Verified

December 1, 2018

Enrollment Period

3.3 years

First QC Date

September 29, 2024

Last Update Submit

October 11, 2024

Conditions

Keywords

InfertilityHysterosalpingographyFertility outcomeoil-based contrast mediumwater-based contrast medium

Outcome Measures

Primary Outcomes (1)

  • live birth

    The primary outcome measure is live birth from pregnancies occurring within 6 months after HSG, defined as a live birth after 24 weeks of gestation, with the last menstrual period starting within six months post-HSG.

    From enrollment to the end of treatment at 6 months

Secondary Outcomes (4)

  • clinical pregnancy

    From enrollment to the end of treatment at 6 months

  • ongoing pregnancy

    From enrollment to the end of treatment at 6 months

  • miscarriage

    From enrollment to the end of treatment at 6 months

  • ectopic pregnancy

    From enrollment to the end of treatment at 6 months

Study Arms (2)

oil-based contrast medium

EXPERIMENTAL

oil-based contrast medium: ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml)

Drug: oil-based contrast medium

warer-based contrast medium

ACTIVE COMPARATOR

water-based contrast medium: Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml)

Drug: water-based contrast medium

Interventions

In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.

oil-based contrast medium

In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.

warer-based contrast medium

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age ≥18 years
  • infertility for at least one year without the use of contraceptives.

You may not qualify if:

  • endocrine disorders, including Cushing's syndrome, hypothalamic amenorrhea, adrenal hyperplasia, diabetes, or thyroid dysfunction (except for well-controlled hypothyroidism with a TSH level between 0.3 and 4.0 mIU/L)
  • known allergy to contrast agents, specifically iodine
  • male partner infertility, defined as post-wash sperm motility \<3 million/mL or \<1 million/mL without sperm washing
  • contraindications for undergoing HSG
  • refusal to provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiao Tong University, School of Medicine

Shanghai, 200030, China

Location

Related Publications (1)

  • Zhu Q, Lu M, Liang G, Wang Y, Xia W, Yan L, Sun T, Mol BW, Zhang J. Oil-based vs. water-based contrast medium in hysterosalpingography for older, anovulatory, and infertile women with high-risk of tubal disease. Eur J Obstet Gynecol Reprod Biol. 2025 Sep;313:114651. doi: 10.1016/j.ejogrb.2025.114651. Epub 2025 Aug 11.

MeSH Terms

Conditions

Infertility

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Study Officials

  • Jian Zhang

    International Peace Maternity and Child Health Hospital affiliated to Shanghai Jiao Tong University, School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants were divided into those who received an oil-based contrast medium (ethiodized poppyseed oil) and a water-based contrast medium (Ioversol) based on a shared medical decision-making process between patients and healthcare providers.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2024

First Posted

October 15, 2024

Study Start

May 4, 2020

Primary Completion

August 30, 2023

Study Completion

December 30, 2023

Last Updated

October 15, 2024

Record last verified: 2018-12

Data Sharing

IPD Sharing
Will share

only IPD used in the publication of the results

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Beginning 3 months and ending 3 years after the publication of results

Locations